CEL-SCI Corporation – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 3 PAGES: 82

More Info
									    CEL-SCI Corporation – Product Pipeline Review – 2012


                                                                                          Reference Code: GMDHC02151CDB
                                                                                                 Publication Date: MAY 2012




CEL-SCI Corporation – Product Pipeline Review – 2012                                      GMDHC02151CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
CEL-SCI Corporation – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
CEL-SCI Corporation Snapshot ......................................................................................................................................................... 6
    CEL-SCI Corporation Overview ..................................................................................................................................................... 6
    Key Information ............................................................................................................................................................................. 6
    Key Facts....................................................................................................................................................................................... 6
CEL-SCI Corporation – Research and Development Overview ......................................................................................................... 7
    Key Therapeutic Areas .................................................................................................................................................................. 7
CEL-SCI Corporation – Pipeline Review .......................................................................................................................................... 10
    Pipeline Products by Stage of Development ............................................................................................................................... 10
    Pipeline Products – Monotherapy ............................................................................................................................................... 11
    Pipeline Products – Combination Treatment Modalities .............................................................................................................. 12
CEL-SCI Corporation – Pipeline Products Glance ........................................................................................................................... 13
    CEL-SCI Corporation – Late Stage Pipeline ................................................................................................................................ 13
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 13
    CEL-SCI Corporation Clinical Stage Pipeline Products ............................................................................................................... 14
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 14
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 15
    CEL-SCI Corporation – Early Stage Pipeline Products ............................................................................................................... 16
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 16
CEL-SCI Corporation – Drug Profiles ............................................................................................................................................... 17
    CEL-1000 .................................................................................................................................................................................... 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 18
    CEL-2000 .................................................................................................................................................................................... 20
        Product Description................................................................................................................................................................. 20
        Mechanism of Action ............................................................................................................................................................... 20
        R&D Progress ......................................................................................................................................................................... 20
    LEAPS-H1N1-DC ........................................................................................................................................................................ 21
        Product Description................................................................................................................................................................. 21
        Mechanism of Action ............................................................................................................................................................... 21
        R&D Progress ......................................................................................................................................................................... 21
    Multikine ...................................................................................................................................................................................... 22
        Product Description................................................................................................................................................................. 22
        Mechanism of Action ............................................................................................................................................................... 22
        R&D Progress ......................................................................................................................................................................... 22
    Multikine + Cisplatin + Radiation Therapy ................................................................................................................................... 24
        Product Description................................................................................................................................................................. 24
        Mechanism of Action ............................................................................................................................................................... 24
        R&D Progress ......................................................................................................................................................................... 24



CEL-SCI Corporation – Product Pipeline Review – 2012                                                                                     GMDHC02151CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                       Page(2)
CEL-SCI Corporation – Product Pipeline Review




    Multikine + Cyclophosphamide + Indomethacin + Zinc................................................................................................................ 26
        Product Description................................................................................................................................................................. 26
        Mechanism of Action ............................................................................................................................................................... 26
        R&D Progress ......................................................................................................................................................................... 26
CEL-SCI Corporation – Pipeline Analysis......................................................................................................................................... 28
    CEL-SCI Corporation – Pipeline Products by Therapeutic Class ................................................................................................ 28
    CEL-SCI Corporation – Pipeline Products By Target .................................................................................................................. 30
    CEL-SCI Corporation – Pipeline Products by Route of Administration ........................................................................................ 31
    CEL-SCI Corporation – Pipeline Products By Mechanism of Action............................................................................................ 32
CEL-SCI Corporation – Recent Pipeline Updates ........................................................................................................................... 33
CEL-SCI Corporation - Dormant Projects ......................................................................................................................................... 38
CEL-SCI Corporation – Company Statement ................................................................................................................................... 39
CEL-SCI Corporation – Locations And Subsidiaries ........................................................................................................................ 41
    Head Office.................................................................................................................................................................................. 41
CEL-SCI Corporation, Recent Developments .................................................................................................................................. 42
    CEL-SCI Corporation- Press Release ......................................................................................................................................... 42
        Dec 01, 2009: CEL-SCI Corporation Retains Global Contract Research Organization (CRO) To Initiate Phase III Clinical Trial
        Of Multikine For Head And Neck Cancers .............................................................................................................................. 42
        Oct 19, 2009: CEL-SCI Presents Data At American College Of Rheumatology Conference Which Suggests That CEL-2000
        Has Potential To Slow Damage Caused By Rheumatoid Arthritis .......................................................................................... 42
Financial Deals Landscape .............................................................................................................................................................. 44
    CEL-SCI Corporation, Deals Summary ....................................................................................................................................... 44
CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deal Details ................................................................................................ 46
    Licensing Agreements ................................................................................................................................................................. 46
        CEL-SCI Enters Into Licensing Agreement With IDC-GP Pharm For Multikine ...................................................................... 46
        CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine ............................................................................ 47
        CEL-SCI Enters Into Licensing Agreement With Byron Biopharma ........................................................................................ 49
        CEL-SCI Enters Into Licensing Agreement With Orient Europharma ..................................................................................... 51
        CEL-SCI Enters Into Licensing Agreement With Teva Pharma .............................................................................................. 52
    Equity Offering ............................................................................................................................................................................. 53
        CEL-SCI Completes Private Placement Of Common Stock For $5.8 Million .......................................................................... 53
        CEL-SCI Completes Registered Direct Offering Of Common Stock For $4 Million ................................................................. 55
        CEL-SCI Announces Private Placement Of $30 Million .......................................................................................................... 57
        CEL-SCI Announces Public Offering Of Upto $34 Million ....................................................................................................... 59
        CEL-SCI Completes Registered Direct Offering Of $20 Million............................................................................................... 60
        CEL-SCI Raises $10 Million Through Exercise Of Warrants................................................................................................... 62
        CEL-SCI Completes Registered Direct Offering Of $5 Million................................................................................................. 64
        CEL-SCI Co
								
To top